Antibody Engineering
Our laboratory is working on the development of novel antibody therapeutics. In particular, we are interested in the engineering of human antibody fragments, which are considerably smaller than current monoclonal antibodies and in the mechanisms of immunomodulation by intravenous immunoglobulin. Human antibody fragments (such as domain antibodies) can be generated by genetic engineering technology, completely bypassing the use of animals. Thus, these fragments can be produced in large quantities in bacteria and open up promising new routes for non-intravenous applications, imaging and therapy. We are applying our technology to targets in cancer and inflammatory diseases.
Staff
 Research AssistantPeter Schofield |
Research Assistant Stephen McKay |
|
 PhD StudentRomain Rouet |
 PhD StudentKip Dudgeon |
|
| Visiting Student Iris Kokmejer |
||
| Emeritius Professor Antony Basten AO FAA FTSE
also holds an appointment in the antibody engineering and
therapeutics group See Professor Basten's Profile |
News
Geoffrey Grigg Travelling Fellowship between Garvan and the MRC Laboratory of Molecular Biology
02 Jun 2010
Garvan and the Medical Research Council's Laboratory of Molecular Biology (LMB), based in Cambridge, have set up the Geoffrey Grigg Travelling Fellowship aimed at enabling short scientific exchange visits between the two institutions.
